eTheRNA immunotherapies and Quantoom Biosciences Announce a Strategic Collaboration for the Development of a Novel RNA Production System

  • The objective is to make RNA therapeutics accessible to global patient populations.  
  • Makes large scale decentralized RNA production economically viable.

Niel and Brussels (Belgium)

eTheRNA immunotherapies NV (‘eTheRNA’), a clinical-stage company developing mRNA-based immunotherapies with in-house GMP certified production and process development capabilities, and Quantoom Biosciences S.A. (“Quantoom”), a biotech company aiming to improve access to essential medicines through innovative bioproduction methods, today announce that they are to collaborate on the development of a revolutionary RNA production system (RPS) for both research and GMP-grade material.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...